Archive | February, 2012

Biotech Bull Market Intact But Due For A Pause

Not A Good Time To Overweight Biotech Positions We are still in a holding pattern and recommend that caution be exercised regarding new positions. Although biotech stocks have made a nice run over the past five days driven by  News from Vivus (VVUS) and Threshold (THLD) the IBB ($119.78) is still off its one year […]

Continue Reading 0

Another Daily Reversal : Take More Off in Biotech

Have you read the book “Think Fast,Think Slow” by Daniel Kahneman? Well my System 1 (fast, intuitive and emotional) brain sees a lot of red on the screen telling me to take profits. If you want System 2 (slower, more deliberative, more logical) data to support this I can only offer the following without extensive […]

Continue Reading 0

Gilead (GILD $46.50) off 15% on Hep-C Clinical Data -Viral Relapse Seen

$11B bet on Pharmasset acquisition for Hepatitus -C drug hits a snag Gilead announced that a majority (6/8) of the hepatitis C genotype-1 patients experienced a viral relapse when treated with GS-7977 Plus Ribavirin. Additional data will be forthcoming by the end of Q1 and Q2. Some analysts saw the stock drop as buying opportunity-11 […]

Continue Reading 0

No Panic Just Take A Little Off:Caution- Update Rally 2/16

Market Reversal and a  Light Sell-Off Technicals and a market reversal particularly a $20+ drop in AAPL gives us reason to take profits or hedge after a great start to 2012. The S&P is up  7% YTD,  NAZ up 12% YTD, and the IBB biotech ETF up 16% YTD near its all time high. Some […]

Continue Reading 0

Rayno Life Science Portfolio Racks-Up More Gains: REGN, RGDX, SRLS

Who Does Not Know About the Bull Market in Biotech Stocks? The bull market in life science stocks gathered momentum today as the IBB rallied 2.34% (up 16.6% YTD) approaching its all time high of $122.45. At some point in time we need to have a correction as this rally is approaching 1999 ebullience. I […]

Continue Reading 0

Response Genetics Raises $7.5M at $1.50 with New CEO

Early Player in Genetic Testing and Personalized Medicine Reloads RGDX Stock Trades Up 36% on Volume of 105k Shares at $1.60 Response Genetics (RGDX)  announced today that it has entered purchase agreements with private investors including current holders to raise more than $7.8M with placement of 5.3M un-registered shares of common stock at a price […]

Continue Reading 0

Biopharma Market Re-Ignited by News and NASDAQ Strength

The IBB hit another new high today at $118.85 as the biotech bull market rolls on. Our index of biopharmaceutical stocks were up 4% at one time propelled by Medivation (MDVN $67.67) up 22% on favorable clinical news on its prostate cancer drug. A WSJ story helped move the stock. Medivation has no revenue and […]

Continue Reading 0